MLN4924: A novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy

Steffan T. Nawrocki, Patrick Griffin, Kevin R. Kelly, Jennifer S. Carew

Research output: Contribution to journalArticle

96 Citations (Scopus)

Abstract

Introduction: The small ubiquitin-like molecule NEDD8 has been identified as an essential regulator of the activity of the cullin-RING E3 ubiquitin ligases (CRLs), which control the turnover of multiple proteins with fundamental roles in cancer biology. The aberrant function of the NEDD8 cascade within the context of malignancy makes it an attractive target for the development of novel anticancer agents. MLN4924 is a first-in-class inhibitor of the proximal regulator of the NEDD8 system (NEDD8-activating enzyme, NAE) that has entered Phase-I trials for cancer therapy and has established that significant therapeutic benefit can be achieved by antagonizing NEDD8-mediated protein degradation. Areas covered: This review provides a detailed overview of the NEDD8 system and discusses the mechanisms of action of MLN4924, a novel small molecule NAE inhibitor. Key findings from preclinical investigations of MLN4924 in a broad range of cancer models and preliminary findings from ongoing Phase-I clinical trials with MLN4924 are also discussed. Expert opinion: Targeting protein NEDDylation represents an exciting new anticancer strategy with demonstrable therapeutic benefit. Ongoing and future studies focused on dissecting the functional status/regulation of the NEDD8 system in individual tumor types will facilitate the design of novel approaches that yield optimal therapeutic benefit.

Original languageEnglish (US)
Pages (from-to)1563-1573
Number of pages11
JournalExpert Opinion on Investigational Drugs
Volume21
Issue number10
DOIs
StatePublished - Oct 2012

Fingerprint

Enzyme Therapy
Neoplasms
Cullin Proteins
Clinical Trials, Phase I
Ubiquitin-Protein Ligases
Expert Testimony
Enzyme Inhibitors
Protein Transport
Therapeutics
Ubiquitin
Antineoplastic Agents
Proteolysis
((1S,2S,4R)-4-(4-((1S)-2,3-dihydro-1H-inden-1-ylamino)-7H-pyrrolo(2,3-d)pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl sulphamate
Enzymes
Proteins

Keywords

  • Cancer
  • MLN4924
  • NEDD8
  • Proteasome
  • Ubiquitin

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

MLN4924 : A novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy. / Nawrocki, Steffan T.; Griffin, Patrick; Kelly, Kevin R.; Carew, Jennifer S.

In: Expert Opinion on Investigational Drugs, Vol. 21, No. 10, 10.2012, p. 1563-1573.

Research output: Contribution to journalArticle

Nawrocki, Steffan T. ; Griffin, Patrick ; Kelly, Kevin R. ; Carew, Jennifer S. / MLN4924 : A novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy. In: Expert Opinion on Investigational Drugs. 2012 ; Vol. 21, No. 10. pp. 1563-1573.
@article{303a0c3ad7ee4439ab386f2d6a27b2c0,
title = "MLN4924: A novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy",
abstract = "Introduction: The small ubiquitin-like molecule NEDD8 has been identified as an essential regulator of the activity of the cullin-RING E3 ubiquitin ligases (CRLs), which control the turnover of multiple proteins with fundamental roles in cancer biology. The aberrant function of the NEDD8 cascade within the context of malignancy makes it an attractive target for the development of novel anticancer agents. MLN4924 is a first-in-class inhibitor of the proximal regulator of the NEDD8 system (NEDD8-activating enzyme, NAE) that has entered Phase-I trials for cancer therapy and has established that significant therapeutic benefit can be achieved by antagonizing NEDD8-mediated protein degradation. Areas covered: This review provides a detailed overview of the NEDD8 system and discusses the mechanisms of action of MLN4924, a novel small molecule NAE inhibitor. Key findings from preclinical investigations of MLN4924 in a broad range of cancer models and preliminary findings from ongoing Phase-I clinical trials with MLN4924 are also discussed. Expert opinion: Targeting protein NEDDylation represents an exciting new anticancer strategy with demonstrable therapeutic benefit. Ongoing and future studies focused on dissecting the functional status/regulation of the NEDD8 system in individual tumor types will facilitate the design of novel approaches that yield optimal therapeutic benefit.",
keywords = "Cancer, MLN4924, NEDD8, Proteasome, Ubiquitin",
author = "Nawrocki, {Steffan T.} and Patrick Griffin and Kelly, {Kevin R.} and Carew, {Jennifer S.}",
year = "2012",
month = "10",
doi = "10.1517/13543784.2012.707192",
language = "English (US)",
volume = "21",
pages = "1563--1573",
journal = "Current Opinion in Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - MLN4924

T2 - A novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy

AU - Nawrocki, Steffan T.

AU - Griffin, Patrick

AU - Kelly, Kevin R.

AU - Carew, Jennifer S.

PY - 2012/10

Y1 - 2012/10

N2 - Introduction: The small ubiquitin-like molecule NEDD8 has been identified as an essential regulator of the activity of the cullin-RING E3 ubiquitin ligases (CRLs), which control the turnover of multiple proteins with fundamental roles in cancer biology. The aberrant function of the NEDD8 cascade within the context of malignancy makes it an attractive target for the development of novel anticancer agents. MLN4924 is a first-in-class inhibitor of the proximal regulator of the NEDD8 system (NEDD8-activating enzyme, NAE) that has entered Phase-I trials for cancer therapy and has established that significant therapeutic benefit can be achieved by antagonizing NEDD8-mediated protein degradation. Areas covered: This review provides a detailed overview of the NEDD8 system and discusses the mechanisms of action of MLN4924, a novel small molecule NAE inhibitor. Key findings from preclinical investigations of MLN4924 in a broad range of cancer models and preliminary findings from ongoing Phase-I clinical trials with MLN4924 are also discussed. Expert opinion: Targeting protein NEDDylation represents an exciting new anticancer strategy with demonstrable therapeutic benefit. Ongoing and future studies focused on dissecting the functional status/regulation of the NEDD8 system in individual tumor types will facilitate the design of novel approaches that yield optimal therapeutic benefit.

AB - Introduction: The small ubiquitin-like molecule NEDD8 has been identified as an essential regulator of the activity of the cullin-RING E3 ubiquitin ligases (CRLs), which control the turnover of multiple proteins with fundamental roles in cancer biology. The aberrant function of the NEDD8 cascade within the context of malignancy makes it an attractive target for the development of novel anticancer agents. MLN4924 is a first-in-class inhibitor of the proximal regulator of the NEDD8 system (NEDD8-activating enzyme, NAE) that has entered Phase-I trials for cancer therapy and has established that significant therapeutic benefit can be achieved by antagonizing NEDD8-mediated protein degradation. Areas covered: This review provides a detailed overview of the NEDD8 system and discusses the mechanisms of action of MLN4924, a novel small molecule NAE inhibitor. Key findings from preclinical investigations of MLN4924 in a broad range of cancer models and preliminary findings from ongoing Phase-I clinical trials with MLN4924 are also discussed. Expert opinion: Targeting protein NEDDylation represents an exciting new anticancer strategy with demonstrable therapeutic benefit. Ongoing and future studies focused on dissecting the functional status/regulation of the NEDD8 system in individual tumor types will facilitate the design of novel approaches that yield optimal therapeutic benefit.

KW - Cancer

KW - MLN4924

KW - NEDD8

KW - Proteasome

KW - Ubiquitin

UR - http://www.scopus.com/inward/record.url?scp=84866532722&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866532722&partnerID=8YFLogxK

U2 - 10.1517/13543784.2012.707192

DO - 10.1517/13543784.2012.707192

M3 - Article

C2 - 22799561

AN - SCOPUS:84866532722

VL - 21

SP - 1563

EP - 1573

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1354-3784

IS - 10

ER -